Patents by Inventor MICHEL SOUCHET

MICHEL SOUCHET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of cephalosporin for treating cancer
    Patent number: 10821114
    Abstract: The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 3, 2020
    Assignees: INSTITUT CURIE, HARMONIC PHARMA
    Inventors: Arnaud Sinan Karaboga, Violeta Isabel Perez-Nueno, Michel Souchet, Didier Decaudin
  • SUBLINGUAL COMPOSITIONS COMPRISING NATURAL EXTRACTS AND USES THEREOF
    Publication number: 20190117555
    Abstract: The present invention relates to a sublingual composition comprising a part of branch extract, preferably from at least one resinous tree comprising at least about 50% by weight of polyphenols and less than about 10% by weight of terpenes, relative to the total weight of the extract. The present invention further relates to the non-therapeutic uses of such sublingual composition for improving the respiratory wellness, relieving joint pain and/or muscular pain and cramps and/or improving endurance, and improving libido and/or fertility.
    Type: Application
    Filed: March 10, 2017
    Publication date: April 25, 2019
    Inventors: ARNAUD SINAN KARABOGA, STEPHANE GEGOUT, MICHEL SOUCHET
  • NEW DERIVATIVES OF CEPHALOSPORIN FOR TREATING CANCER
    Publication number: 20170119784
    Abstract: The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
    Type: Application
    Filed: April 2, 2015
    Publication date: May 4, 2017
    Inventors: ARNAUD SINAN KARABOGA, VIOLETA ISABEL PEREZ-NUENO, MICHEL SOUCHET, DIDIER DECAUDIN